SCHEMBL160848

SCHEMBL160848

COC(=O)C(C)(C)CCc1ncc(-c2ccc(N)cc2)s1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ERCC5 P28715 1/20 0.38
FEN1 P39748 1/20 0.38
CYP3A4 P08684 3/20 0.37
CSNK2A1 P68400 2/20 0.36
LOXL2 Q9Y4K0 2/20 0.36
NPC1 O15118 2/20 0.35
ALDH1A1 P00352 2/20 0.35
MAPT P10636 2/20 0.35
RAB9A P51151 2/20 0.35
SMN1; SMN2 Q16637 2/20 0.35
MEN1 O00255 1/20 0.35
LMNA P02545 1/20 0.35
GAA P10253 1/20 0.35
ALOX15 P16050 1/20 0.35
KMT2A Q03164 1/20 0.35
HSD17B10 Q99714 1/20 0.35
PDPK1 O15530 1/20 0.35
TMPRSS15 P98073 2/20 0.34
APP P05067 1/20 0.34
CSNK2A2 P19784 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL164309 0.89 ERCC5 (0.40) ERCC5FEN1CYP3A4CSNK2A1LOXL2
SCHEMBL162847 0.84 CYP2C19 (0.47) ERCC5FEN1CSNK2A1NPC1ALDH1A1
SCHEMBL162879 0.83 RAB9A (0.44) NPC1RAB9ASMN1; SMN2MEN1KMT2A
SCHEMBL161205 0.82 MAPT (0.46) CSNK2A1NPC1ALDH1A1MAPTRAB9A
SCHEMBL164809 0.82 MAPT (0.42) NPC1MAPTRAB9ASMN1; SMN2MEN1
SCHEMBL160755 0.80 ERCC5 (0.41) ERCC5FEN1CYP3A4CSNK2A1LOXL2
SCHEMBL163250 0.80 DGAT1 (0.54) MAPTSMN1; SMN2LMNADGAT1HDAC6
SCHEMBL161575 0.79 LOXL2 (0.36) ERCC5FEN1CYP3A4CSNK2A1LOXL2
SCHEMBL160962 0.79 ALDH1A1 (0.42) ALDH1A1MAPTSMN1; SMN2MEN1LMNA
SCHEMBL161659 0.79 PTPN1 (0.48) CSNK2A1CSNK2A2DGAT1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2611783-A2 HETEROCYCLIC COMPOUNDS AS DGAT1 INHIBITORS Piramal Enterprises Limited (IN) 2013-07-10 EP disclosed
US-20130158075-A1 HETEROCYCLIC COMPOUNDS AS DGAT1 INHIBITORS Piramal Enterprises Limited (IN) 2013-06-20 US disclosed
WO-2012029032-A2 HETEROCYCLIC COMPOUNDS AS DGAT1 INHIBITORS PIRAMAL LIFE SCIENCES LIMITED (IN) 2012-03-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130158075-A1 HETEROCYCLIC COMPOUNDS AS DGAT1 INHIBITORS DGAT1, DGAT2, SOAT1 ERCC5 4116/4885FEN1 3792/4885CYP3A4 1000/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.